[go: up one dir, main page]

MX2022013006A - Inhibidor de bcl-2. - Google Patents

Inhibidor de bcl-2.

Info

Publication number
MX2022013006A
MX2022013006A MX2022013006A MX2022013006A MX2022013006A MX 2022013006 A MX2022013006 A MX 2022013006A MX 2022013006 A MX2022013006 A MX 2022013006A MX 2022013006 A MX2022013006 A MX 2022013006A MX 2022013006 A MX2022013006 A MX 2022013006A
Authority
MX
Mexico
Prior art keywords
bcl
inhibitor
compound
disclosed
inhibiting
Prior art date
Application number
MX2022013006A
Other languages
English (en)
Inventor
Yunhang Guo
Zhiwei Wang
Hai Xue
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Publication of MX2022013006A publication Critical patent/MX2022013006A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

En la presente se describe un compuesto de la Fórmula (I) para inhibir tanto Bcl-2 de tipo silvestre como Bcl-2 mutado, en particular, Bcl-2 G101V y D103Y, y un método para usar el compuesto divulgado en la presente para el tratamiento contra enfermedades apoptóticas no reguladas.
MX2022013006A 2020-04-15 2021-04-14 Inhibidor de bcl-2. MX2022013006A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CN2020084992 2020-04-15
CN2020100472 2020-07-06
CN2020125580 2020-10-30
CN2021075831 2021-02-07
CN2021086189 2021-04-09
PCT/CN2021/087225 WO2021208963A1 (en) 2020-04-15 2021-04-14 Bcl-2 inhibitor

Publications (1)

Publication Number Publication Date
MX2022013006A true MX2022013006A (es) 2023-01-11

Family

ID=78083530

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013006A MX2022013006A (es) 2020-04-15 2021-04-14 Inhibidor de bcl-2.

Country Status (13)

Country Link
US (3) US12286430B2 (es)
EP (1) EP4136084A4 (es)
JP (1) JP2023520843A (es)
KR (1) KR20230002419A (es)
CN (3) CN116802179A (es)
AU (1) AU2021256580A1 (es)
BR (1) BR112022019525A2 (es)
CA (1) CA3172478A1 (es)
IL (1) IL296582A (es)
MX (1) MX2022013006A (es)
TW (1) TW202200574A (es)
WO (1) WO2021208963A1 (es)
ZA (1) ZA202209891B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL296582A (en) * 2020-04-15 2022-11-01 Beigene Ltd bcl-2 inhibitor
WO2022213335A1 (en) * 2021-04-09 2022-10-13 Beigene (Beijing) Co., Ltd. Method for preparing intermediate of bcl-2 inhibitor
WO2023078398A1 (en) * 2021-11-05 2023-05-11 Fochon Pharmaceuticals, Ltd. Compounds as bcl-2 inhibitors
JP2024540590A (ja) * 2021-11-20 2024-10-31 フォチョン・バイオサイエンシーズ・リミテッド Ｂｃｌ－２阻害剤としての化合物
KR20240135747A (ko) * 2021-12-06 2024-09-12 항저우 힐젠 테라퓨틱스 컴퍼니 리미티드 항-세포사멸 단백질 bcl-2 억제제, 약학적 조성물 및 이의 응용
WO2023122000A1 (en) * 2021-12-20 2023-06-29 Newave Pharmaceutical Inc. Bcl-2 inhibitors
CN114292192A (zh) * 2022-01-17 2022-04-08 山东泓瑞医药科技股份公司 一种3,4-二甲氧基苯甲酸甲酯的合成方法
KR20240161147A (ko) 2022-03-14 2024-11-12 슬랩 파마슈티컬스 엘엘씨 다중 사이클릭 화합물
WO2023231777A1 (en) * 2022-06-01 2023-12-07 Fochon Pharmaceuticals, Ltd. Compounds as bcl-2 inhibitors

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR031130A1 (es) 2000-09-20 2003-09-10 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
US20020055631A1 (en) 2000-09-20 2002-05-09 Augeri David J. N-acylsulfonamide apoptosis promoters
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
AU2005277223C1 (en) 2004-08-20 2009-05-21 The Regents Of The University Of Michigan Small molecule inhibitors of anti-apoptotic Bcl-2 family members and the uses thereof
EP1888550B1 (en) 2005-05-12 2014-06-25 AbbVie Bahamas Ltd. Apoptosis promoters
MX2007014783A (es) 2005-05-24 2008-02-19 Abbott Lab Activadores de apoptosis.
WO2008030836A2 (en) 2006-09-05 2008-03-13 Abbott Laboratories Bcl inhibitors treating platelet excess
WO2009036051A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Bcl-2 inhibitors containing a zinc binding moiety
ATE540026T1 (de) 2008-06-09 2012-01-15 Bristol Myers Squibb Co Hydroxyphenylsulfonsäureamide als antiapoptotische bcl-inhibitoren
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
UA108193C2 (uk) 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
CA2744711C (en) 2008-12-05 2017-06-27 Abbott Laboratories Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
EP2373629B1 (en) 2008-12-08 2013-04-10 Boehringer Ingelheim International Gmbh Compounds for treating cancer
PL2511264T3 (pl) 2009-01-19 2015-08-31 Abbvie Inc Środki indukujące apoptozę do leczenia raka oraz chorób immunologicznych i autoimmunologicznych
AU2010204555B2 (en) 2009-01-19 2013-03-07 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
PE20120345A1 (es) 2009-05-26 2012-05-17 Abbvie Bahamas Ltd Derivados de 2-(1h-pirrolo[2,3-b]piridin-5-iloxi)-n-fenilsulfonilbenzamida como inhibidores de proteinas anti-apoptoticas
CN102498111A (zh) 2009-09-10 2012-06-13 诺瓦提斯公司 作为Bcl-2家族蛋白抑制剂用于癌症的治疗的磺酰胺化合物
EP2957558A3 (en) 2010-03-25 2016-03-02 AbbVie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI520960B (zh) 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
TWI535712B (zh) 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
NZ608274A (en) 2010-10-29 2015-05-29 Abbvie Inc Solid dispersions containing an apoptosis-inducing agent
IT1403156B1 (it) 2010-12-01 2013-10-04 Università Degli Studi Di Torino Inibitori di fosfatidilinositol 3-chinasi, relative composizioni ed usi.
US8691184B2 (en) 2011-01-25 2014-04-08 The Regents Of The University Of Michigan Bcl-2/Bcl-xL inhibitors and therapeutic methods using the same
EP2714681B1 (en) 2011-05-25 2015-06-24 Bristol-Myers Squibb Company Substituted sulfonamides useful as antiapoptotic bcl inhibitors
WO2013053045A1 (en) 2011-10-12 2013-04-18 Beta Pharma Canada Inc. Heterocyclic molecules as apoptosis inducers
US9029820B2 (en) 2011-12-22 2015-05-12 Saint-Gobain Ceramics & Plastics, Inc. Image storage device including storage phosphor powder, method of forming image storage device, and computed radiography apparatus
EA201491259A1 (ru) 2011-12-23 2014-11-28 Новартис Аг Соединения и композиции для ингибирования взаимодействия bcl2 с партнерами связывания
MX2014007731A (es) 2011-12-23 2015-01-12 Novartis Ag Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace.
EA201491265A1 (ru) 2011-12-23 2014-11-28 Новартис Аг Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию
MX2014007729A (es) 2011-12-23 2015-01-12 Novartis Ag Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace.
WO2013185202A1 (en) 2012-06-14 2013-12-19 Beta Pharma Canada Inc Apoptosis inducers
US9096625B2 (en) 2013-01-16 2015-08-04 The Regents Of The University Of Michigan BCL-2/BCL-XL inhibitors and therapeutic methods using the same
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN104884458B (zh) 2013-04-25 2017-04-12 百济神州有限公司 作为蛋白质激酶抑制剂的稠合杂环化合物
AU2014339816B2 (en) 2013-10-25 2020-05-28 Pharmacyclics Llc Treatment using Bruton's tyrosine kinase inhibitors and immunotherapy
DK3179991T3 (da) 2014-08-11 2021-12-06 Acerta Pharma Bv Terapeutiske kombinationer af en btk-inhibitor og en bcl-2-inhibitor
WO2017132474A1 (en) 2016-01-30 2017-08-03 Newave Pharmaceutical Inc. Bcl-2 inhibitors
US20190225607A1 (en) 2016-07-06 2019-07-25 Concert Pharmaceuticals, Inc. Deuterated Venetoclax
LT3494115T (lt) 2016-08-05 2021-01-25 The Regents Of The University Of Michigan N-(fenilsulfonil)benzamido dariniai kaip bcl-2 inhibitoriai
CN109641897B (zh) 2016-09-01 2021-12-07 北京赛林泰医药技术有限公司 Bcl-2选择性抑制剂及其制备和用途
CN106565706B (zh) 2016-10-27 2018-05-01 广东东阳光药业有限公司 一种磺酰胺衍生物及其在药学中的应用
CN106749233B (zh) * 2016-11-24 2020-04-21 中山大学 一类磺酰胺衍生物及其应用
CN108002087B (zh) * 2017-01-03 2019-05-10 东莞理工学院 一种多种宽度规格的新旧smt接料带的粘接机
WO2018127130A1 (en) 2017-01-07 2018-07-12 Shanghai Fochon Pharmaceutical Co., Ltd. Compounds as bcl-2-selective apoptosis-inducing agents
PT3612531T (pt) 2017-04-18 2022-10-04 Shanghai Fochon Pharmaceutical Co Ltd Agentes indutores de apoptose
ES3028360T3 (en) 2017-06-26 2025-06-19 Shenzhen Targetrx Inc Deuterated n-benzenesulfonylbenzamide compound for inhibiting bcl-2 protein and composition and use thereof
CN111511748B (zh) 2017-08-23 2023-05-02 广州麓鹏制药有限公司 Bcl-2抑制剂
FR3072679B1 (fr) 2017-10-25 2020-10-30 Servier Lab Nouveaux derives macrocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN110143974B (zh) 2018-02-11 2021-07-13 中国科学院上海药物研究所 一类新型青蒿素衍生物、合成方法及其用途
US11420968B2 (en) 2018-04-29 2022-08-23 Beigene, Ltd. Bcl-2 inhibitors
CN110772521A (zh) 2018-07-31 2020-02-11 苏州亚盛药业有限公司 Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
AU2019314819A1 (en) 2018-07-31 2020-10-22 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of Bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
WO2020140005A2 (en) * 2018-12-29 2020-07-02 Newave Pharmaceutical Inc. Bcl-2 inhibitors
CN114929689B (zh) 2019-10-28 2024-08-27 百济神州有限公司 Bcl-2抑制剂
WO2021110102A1 (en) 2019-12-02 2021-06-10 Beigene, Ltd. Methods of cancer treatment using bcl-2 inhibitor
IL296582A (en) 2020-04-15 2022-11-01 Beigene Ltd bcl-2 inhibitor
WO2022213335A1 (en) 2021-04-09 2022-10-13 Beigene (Beijing) Co., Ltd. Method for preparing intermediate of bcl-2 inhibitor
PH12023553203A1 (en) 2021-06-02 2024-02-19 Beigene Switzerland Gmbh Methods of treating b-cell malignancy using bcl-2 inhibitor
TW202328125A (zh) 2021-08-31 2023-07-16 英屬開曼群島商百濟神州有限公司 Bcl-2抑制劑的固體形式、製備方法及其用途
TW202400163A (zh) 2022-05-12 2024-01-01 英屬開曼群島商百濟神州有限公司 使用ｂｃｌ－２抑制劑治療髓性惡性腫瘤之方法
CA3262418A1 (en) 2022-07-21 2024-01-25 Beigene Switzerland Gmbh METHODS OF TREATMENT OF MULTIPLE MYELOMA USING A BCL-2 INHIBITOR

Also Published As

Publication number Publication date
US20240376097A1 (en) 2024-11-14
BR112022019525A2 (pt) 2023-11-14
US20230159522A1 (en) 2023-05-25
ZA202209891B (en) 2023-05-31
TW202200574A (zh) 2022-01-01
AU2021256580A1 (en) 2022-09-29
IL296582A (en) 2022-11-01
US12286430B2 (en) 2025-04-29
CA3172478A1 (en) 2021-10-21
CN116969936A (zh) 2023-10-31
JP2023520843A (ja) 2023-05-22
CN116969937A (zh) 2023-10-31
CN116802179A (zh) 2023-09-22
KR20230002419A (ko) 2023-01-05
US20250270210A1 (en) 2025-08-28
WO2021208963A1 (en) 2021-10-21
EP4136084A4 (en) 2023-11-01
EP4136084A1 (en) 2023-02-22

Similar Documents

Publication Publication Date Title
MX2022013006A (es) Inhibidor de bcl-2.
MX2024001893A (es) Compuestos heterociclicos y metodos de uso.
MX2023012726A (es) Compuestos heterociclicos y metodos de uso.
NZ787393A (en) New methylquinazolinone derivatives
MX2024000271A (es) Inhibidor de shp2 y uso del mismo.
EA200800006A1 (ru) Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i
WO2024026433A3 (en) Novel dpp1 inhibitors and uses thereof
TW200510397A (en) Conjugated complement cascade inhibitors
PH12023552079A1 (en) Cdk2 inhibitors and methods of using the same
PH12022550124A1 (en) Enzyme inhibitors
PH12022550130A1 (en) Enzyme inhibitors
ZA202212095B (en) Il4i1 inhibitors and methods of use
PH12022550491A1 (en) Perk inhibiting pyrrolopyrimidine compounds
PH12022550045A1 (en) Plasma kallikrein inhibitors
WO2022119858A8 (en) Compounds for the treatment of sars
MX2025013435A (es) Derivados de carboxamida heteroaromatica como inhibidores de la calicreina plasmatica
PH12022550497A1 (en) Perk inhibiting compounds
CA3241698A1 (en) Methionine adenosyltransferase 2a heterocyclic inhibitor
WO2024026483A3 (en) Cdk2 inhibitors and methods of using the same
WO2024026479A3 (en) Cdk2 inhibitors and methods of using the same
WO2024026486A3 (en) Cdk2 inhibitors and methods of using the same
MX2022014303A (es) Compuestos para el tratamiento del sars.
WO2024026484A3 (en) Cdk2 inhibitors and methods of using the same
WO2019195641A3 (en) 1,3,4-oxadiazoles as inhibitors of rho/mrtf/srf-mediated gene transcription and methods for use of the same
ZA202106519B (en) Caspase inhibitors and methods of use thereof